猫咪视频

Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Total
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Deficit
Beginning balance (in shares) at Apr. 30, 2021 25,066,297
Beginning balance at Apr. 30, 2021 $ 49,090,474 $ 25,067 $ 109,040,824 $ (1,817,414) $ (58,158,003)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation 1,264,870 1,264,870
Common stock issued for vested restricted stock units (in shares) 34,989
Common stock issued for vested restricted stock units 0 $ 35 (35)
Common stock issued for stock options exercised for cash (in shares) 16,752
Common stock issued for stock options exercised for cash 56,034 $ 17 56,017
Common stock issued for cashless stock options exercised (in shares) 30,156
Common stock issued for cashless stock options exercised 0 $ 30 (30)
Amortization of warrant based cost 27,583 27,583
Warrants issued for deferred financing costs related to Credit Facility 137,500 137,500
Net loss (3,723,146) (3,723,146)
Ending balance (in shares) at Oct. 31, 2021 25,148,194
Ending balance at Oct. 31, 2021 46,853,315 $ 25,149 110,526,729 (1,817,414) (61,881,149)
Beginning balance (in shares) at Jul. 31, 2021 25,087,051
Beginning balance at Jul. 31, 2021 48,796,304 $ 25,088 109,617,521 (1,817,414) (59,028,891)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation 722,158 722,158
Common stock issued for vested restricted stock units (in shares) 19,332
Common stock issued for vested restricted stock units 0 $ 19 (19)
Common stock issued for stock options exercised for cash (in shares) 11,655
Common stock issued for stock options exercised for cash 33,486 $ 12 33,474
Common stock issued for cashless stock options exercised (in shares) 30,156
Common stock issued for cashless stock options exercised 0 $ 30 (30)
Amortization of warrant based cost 16,125 16,125
Warrants issued for deferred financing costs related to Credit Facility 137,500 137,500
Net loss (2,852,258) (2,852,258)
Ending balance (in shares) at Oct. 31, 2021 25,148,194
Ending balance at Oct. 31, 2021 $ 46,853,315 $ 25,149 110,526,729 (1,817,414) (61,881,149)
Beginning balance (in shares) at Apr. 30, 2022 25,202,278 25,357,764
Beginning balance at Apr. 30, 2022 $ 42,545,724 $ 25,358 112,081,564 (1,817,414) (67,743,784)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation 504,666 504,666
Common stock issued for vested restricted stock units (in shares) 66,245
Common stock issued for vested restricted stock units 0 $ 66 (66)
Common stock issued for services (in shares) 25,000
Common stock issued for services 24,500 $ 25 24,475
Common stock issued for equity raise, net of underwriter costs (in shares) 11,840
Common stock issued for equity raise, net of underwriter costs 9,535 $ 12 9,523
Amortization of warrant based cost 14,000 14,000
Net loss $ (6,008,611) (6,008,611)
Ending balance (in shares) at Oct. 31, 2022 25,305,363 25,460,849
Ending balance at Oct. 31, 2022 $ 37,089,814 $ 25,461 112,634,162 (1,817,414) (73,752,395)
Beginning balance (in shares) at Jul. 31, 2022 25,357,764
Beginning balance at Jul. 31, 2022 38,884,083 $ 25,358 112,134,894 (1,817,414) (71,458,755)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation 458,336 458,336
Common stock issued for vested restricted stock units (in shares) 66,245
Common stock issued for vested restricted stock units 0 $ 66 (66)
Common stock issued for services (in shares) 25,000
Common stock issued for services 24,500 $ 25 24,475
Common stock issued for equity raise, net of underwriter costs (in shares) 11,840
Common stock issued for equity raise, net of underwriter costs 9,535 $ 12 9,523
Amortization of warrant based cost 7,000 7,000
Net loss $ (2,293,640) (2,293,640)
Ending balance (in shares) at Oct. 31, 2022 25,305,363 25,460,849
Ending balance at Oct. 31, 2022 $ 37,089,814 $ 25,461 $ 112,634,162 $ (1,817,414) $ (73,752,395)